31 March 2022
Bio Products Laboratory Ltd (BPL), a leading manufacturer of plasma-derived protein therapies, today marks the end of Bleeding Disorders Awareness Month1. Recognised every March, this month aims to help raise awareness of inheritable blood and bleeding disorders and the 300 million people affected by them worldwide.
Some of the most common (though still extremely rare) bleeding disorders include haemophilia, von Willebrand disease and rare factor deficiencies. These disorders share the inability to form proper blood clots due to a lack of clotting factor proteins in the blood. As a result, people with bleeding disorders experience unexplained bruising, spontaneous bleeding, and excessive bleeding after an injury.
By processing plasma collected from its donor communities, BPL manufactures its plasma-derived therapies, some of which are particularly relevant to the treatment of bleeding disorders.
In September, BPL announced the kick-off of the Hereditary Factor X Deficiency in America Survey, the first of its kind focusing on patients suffering from this ultra-rare bleeding disorder.
The survey, designed to collect information on a patient and/or caregiver's journey throughout the early symptoms, diagnosis, and treatment of this ultra-rare bleeding disorder, is being offered to individuals with or impacted by hereditary factor X deficiency through haemophilia treatment centres and haematology specialty offices in the United States. Patients or caregivers are prompted to answer questions related to how symptoms, treatments, and other related factors impact their daily living and quality of life.
BPL will also participate in three major scientific events this year and a major patient-focused educational conference to support the international bleeding disorders community.
In May, BPL will attend the WFH 2022 World Congress, which is the first major hybrid event, where the World Federation of Hemophilia (WFH) and the Canadian Hemophilia Society (CHS) will welcome the global bleeding disorders community in Montreal, Canada.
In July, BPL will be presenting at the International Society on Thrombosis and Haemostasis (ISTH) Congress in London, which brings together thousands of the world’s leading experts in the field of thrombosis, haemostasis and vascular biology. BPL will provide a scientific presentation on rare bleeding disorder therapies during a product theatre targeted at healthcare professionals.
In August, BPL intends to present data from a rare bleeding disorders registry at the Thrombosis and Haemostasis Societies of North America (THSNA) meeting in Chicago. BPL will also be participating in the National Hemophilia Foundation’s (NHF) Annual Bleeding Disorders Conference in Houston, Texas.
Bob Rossilli, Chief Commercial Officer, Global Business, said, “We are proud to join the bleeding disorders’ community in raising awareness, dialogue and understanding around rare bleeding disorders.
“Led by US and UK-based specialists and using the latest developments in medical science and clinical practice, BPL is committed to treating and improving the lives of every patient living with a rare bleeding disorder who relies on access to plasma protein therapies.
“We look forward to joining WFH 2022, ISTH 2022, THSNA and NHF this year, so that we can provide attendees with the opportunity to hear more about the important work we do at BPL.”
Donna Mitchell, BPL Communications Manager
About Bio Products Laboratory (BPL)
Recognising the importance of plasma and with many years of experience in the industry, BPL supplies high-quality plasma derived medicines to meet the needs of clinicians, patients, and customers globally. Headquartered in the United Kingdom, with US offices in Durham, NC, and plasma collection centres across the United States, we are dedicated to producing medicines for the treatment of immune deficiencies, bleeding disorders and infectious diseases as well for critical care. BPL invests in the latest R&D, technology and manufacturing methods, and continuously adapts to ensure that we continue to serve all our stakeholders effectively. For more information visit http://www.bplgroup.com or https://www.bpl-us.com.
BPL consists of two operating divisions — BPL Plasma and BPL Therapeutics. BPL Plasma, headquartered in Austin, Texas and operating in the USA, collects plasma from donors in around 28 centers across the U.S. BPL Plasma employs over 900 staff to support the needs of donors and to ensure high-quality plasma collection in all their centers. Plasma collection is regulated by both FDA and MHRA, and BPL Plasma follows industry guidelines. BPL Plasma operates plasma facilities, staffed with trained personnel, dedicated to supporting donors through the process that leads to the donation of plasma. Plasma is shipped to the headquarters of BPL Therapeutics in Elstree, United Kingdom. The plasma is fractionated, purified, and filled through the efforts of our over 1,000 employees involved in production, quality, R&D, commercial, customer services, and administrative activities. BPL’s plasma-derived medicines are commercially available in the U.K., USA, and 30 plus other countries around the world through our network of local affiliates and distribution partners.